{ "cells": [ { "cell_type": "code", "execution_count": 44, "metadata": {}, "outputs": [ { "name": "stderr", "output_type": "stream", "text": [ "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/transformers/tokenization_utils_base.py:1617: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be deprecated in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n", " warnings.warn(\n" ] } ], "source": [ "from langchain_community.agent_toolkits import create_sql_agent\n", "from langchain_openai import ChatOpenAI\n", "from langchain_groq import ChatGroq\n", "from langchain_core.prompts import ChatPromptTemplate\n", "from langchain_core.pydantic_v1 import BaseModel, Field\n", "import pandas as pd\n", "from pydantic import BaseModel, Field\n", "\n", "from langchain.text_splitter import RecursiveCharacterTextSplitter\n", "from langchain_community.vectorstores import Chroma\n", "from langchain.embeddings import HuggingFaceEmbeddings\n", "from langchain_core.runnables import RunnablePassthrough\n", "from langchain_core.output_parsers import StrOutputParser\n", "\n", "\n", "gpt = ChatOpenAI(model=\"gpt-3.5-turbo\", temperature=0)\n", "#agent_gpt_executor = create_sql_agent(gpt, db=db, agent_type=\"tool-calling\", verbose=True)\n", "\n", "## make database\n", "from langchain_community.utilities import SQLDatabase\n", "from sqlalchemy import create_engine\n", "\n", "from langchain.prompts import ChatPromptTemplate\n", "from langchain.schema import SystemMessage\n", "from langchain_core.prompts import MessagesPlaceholder\n", "#agent_groq_executor = create_sql_agent(llm, db=db, agent_type=\"tool-calling\", verbose=True)\n", "\n", "from OpenAITools.FetchTools import fetch_clinical_trials, fetch_clinical_trials_jp\n", "from OpenAITools.CrinicalTrialTools import QuestionModifierEnglish, TumorNameExtractor, SimpleClinicalTrialAgent,GraderAgent,LLMTranslator,generate_ex_question_English\n", "\n", "from OpenAITools.JRCTTools import get_matched_df\n", "from sentence_transformers import SentenceTransformer\n", "from sentence_transformers import util\n", "groq = ChatGroq(model_name=\"llama3-70b-8192\", temperature=0)\n", "#agent_groq_executor = create_sql_agent(groq, db=db, agent_type=\"tool-calling\", verbose=True)\n", "\n", "import ast\n", "import torch\n", "age = \"65\"\n", "sex =\"男性\"\n", "tumor_type =\"glioma\"\n", "#tumor_type = \"gastric cancer\"\n", "GeneMutation =\"HER2\"\n", "Meseable = \"有り\"\n", "Biopsiable = \"有り\"\n", "NCTID = 'NCT06441994'\n", "\n", "#Define extractor\n", "Translator = LLMTranslator(groq)\n", "TumorName = Translator.translate(tumor_type)\n", "selectionModel = SentenceTransformer('pritamdeka/S-PubMedBert-MS-MARCO')\n", "ex_question = generate_ex_question_English(age, sex, TumorName, GeneMutation, Meseable, Biopsiable)" ] }, { "cell_type": "code", "execution_count": 45, "metadata": {}, "outputs": [], "source": [ "basedf = pd.read_csv(\"../ClinicalTrialCSV/JRCT20241215CancerPost.csv\", index_col=0)" ] }, { "cell_type": "code", "execution_count": 46, "metadata": {}, "outputs": [ { "name": "stderr", "output_type": "stream", "text": [ "/var/folders/yw/qz00x75d7kb98f7vm8dkhkvw0000gn/T/ipykernel_49357/2492212482.py:2: SettingWithCopyWarning: \n", "A value is trying to be set on a copy of a slice from a DataFrame.\n", "Try using .loc[row_indexer,col_indexer] = value instead\n", "\n", "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n", " df['AgentJudgment'] = None\n", "/var/folders/yw/qz00x75d7kb98f7vm8dkhkvw0000gn/T/ipykernel_49357/2492212482.py:3: SettingWithCopyWarning: \n", "A value is trying to be set on a copy of a slice from a DataFrame.\n", "Try using .loc[row_indexer,col_indexer] = value instead\n", "\n", "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n", " df['AgentGrade'] = None\n" ] } ], "source": [ "df = get_matched_df(basedf=basedf, query=TumorName, model=selectionModel, threshold=0.925)\n", "df['AgentJudgment'] = None\n", "df['AgentGrade'] = None" ] }, { "cell_type": "code", "execution_count": 47, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTargetJTargetTargetEnglish研究・治験の目的試験等のフェーズ試験の種類...Age MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)TargetWordTargetVecAgentJudgmentAgentGrade
82jRCT2051240121NCT06413706NaN放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...悪性神経膠腫悪性神経膠腫High-Grade Glioma放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...2NaN...No limit21age old notNaNNaNNaNDrug: Abemaciclib Administered orally Other Na...['High-Grade Glioma'][[-0.12244764715433121, -0.5778073668479919, -...NoneNone
175jRCT2031240090NaNNaN再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...悪性神経膠腫悪性神経膠腫Malignant glioma再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl...3NaN...18age old over75age old underBothNaNglioblastoma, grade3/4 astrocytoma, grade3 oli...Group A: BPC Therapy Depending on the patient'...['Malignant Glioma'][[-0.33767956495285034, -0.4648125171661377, -...NoneNone
263jRCT2041230136NaNNaN再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験再発膠芽腫再発膠芽腫recurrent glioblastoma再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を...1NaN...18age old over75age old underBothNaNNaNDosing frequency: 1 time /week Dose Levels Lev...['Recurrent', 'Glioblastoma'][[-0.27501848340034485, -0.5264514088630676, -...NoneNone
361jRCT2051230069NaNNaN神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...神経膠腫神経膠腫Glioma神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併用療法の安全...1NaN...18age old overNo limitBothNaNNaN<cohort1> Lomustine 130 mg/m2 orally every 6 w...['Glioma'][[-0.21631155908107758, -0.5687925219535828, -...NoneNone
414jRCT2031230007NaNNaNBRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医...低悪性度神経膠腫、膵癌低悪性度神経膠腫、膵癌Low-grade glioma, pancreatic cancerBRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫(コホート A...2NaN...12age old overNo limitBothNaNBRAF fusion gene, BRAF rearrangement, low-grad...Binimetinib is administered 45 mg orally, twic...['Low-Grade Glioma', 'Pancreatic Cancer'][[-0.18604964017868042, -0.547483503818512, -0...NoneNone
636jRCT2031210299NaNNaN再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験再発悪性神経膠腫再発悪性神経膠腫Recurrent High-Grade Glioma再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...1NaN...18age old overNo limitBothNaNNaNPatients will receive DSP-0390 orally once dai...['Recurrent', 'High-Grade Glioma'][[-0.2750183045864105, -0.5264511704444885, -0...NoneNone
712jRCT2031200153NaNNaNCellm-001による初発膠芽腫治療効果無作為比較対照試験膠芽腫膠芽腫glioblastoma脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...3NaN...18age old over75age old underBothNaNNaNInject the investigational drug (Cellm-001 or ...['Glioblastoma'][[-0.15113382041454315, -0.5002245306968689, -...NoneNone
\n", "

7 rows × 43 columns

\n", "
" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "82 jRCT2051240121 NCT06413706 NaN \n", "175 jRCT2031240090 NaN NaN \n", "263 jRCT2041230136 NaN NaN \n", "361 jRCT2051230069 NaN NaN \n", "414 jRCT2031230007 NaN NaN \n", "636 jRCT2031210299 NaN NaN \n", "712 jRCT2031200153 NaN NaN \n", "\n", " Title TargetJ \\\n", "82 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... 悪性神経膠腫 \n", "175 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... 悪性神経膠腫 \n", "263 再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験 再発膠芽腫 \n", "361 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 神経膠腫 \n", "414 BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医... 低悪性度神経膠腫、膵癌 \n", "636 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 再発悪性神経膠腫 \n", "712 Cellm-001による初発膠芽腫治療効果無作為比較対照試験 膠芽腫 \n", "\n", " Target TargetEnglish \\\n", "82 悪性神経膠腫 High-Grade Glioma \n", "175 悪性神経膠腫 Malignant glioma \n", "263 再発膠芽腫 recurrent glioblastoma \n", "361 神経膠腫 Glioma \n", "414 低悪性度神経膠腫、膵癌 Low-grade glioma, pancreatic cancer \n", "636 再発悪性神経膠腫 Recurrent High-Grade Glioma \n", "712 膠芽腫 glioblastoma \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 ... \\\n", "82 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... 2 NaN ... \n", "175 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl... 3 NaN ... \n", "263 再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を... 1 NaN ... \n", "361 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併用療法の安全... 1 NaN ... \n", "414 BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫(コホート A... 2 NaN ... \n", "636 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... 1 NaN ... \n", "712 脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術... 3 NaN ... \n", "\n", " Age Minimum Age Maximum Gender Discontinuation Criteria \\\n", "82 No limit 21age old not NaN NaN \n", "175 18age old over 75age old under Both NaN \n", "263 18age old over 75age old under Both NaN \n", "361 18age old over No limit Both NaN \n", "414 12age old over No limit Both NaN \n", "636 18age old over No limit Both NaN \n", "712 18age old over 75age old under Both NaN \n", "\n", " Keyword \\\n", "82 NaN \n", "175 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n", "263 NaN \n", "361 NaN \n", "414 BRAF fusion gene, BRAF rearrangement, low-grad... \n", "636 NaN \n", "712 NaN \n", "\n", " Intervention(s) \\\n", "82 Drug: Abemaciclib Administered orally Other Na... \n", "175 Group A: BPC Therapy Depending on the patient'... \n", "263 Dosing frequency: 1 time /week Dose Levels Lev... \n", "361 Lomustine 130 mg/m2 orally every 6 w... \n", "414 Binimetinib is administered 45 mg orally, twic... \n", "636 Patients will receive DSP-0390 orally once dai... \n", "712 Inject the investigational drug (Cellm-001 or ... \n", "\n", " TargetWord \\\n", "82 ['High-Grade Glioma'] \n", "175 ['Malignant Glioma'] \n", "263 ['Recurrent', 'Glioblastoma'] \n", "361 ['Glioma'] \n", "414 ['Low-Grade Glioma', 'Pancreatic Cancer'] \n", "636 ['Recurrent', 'High-Grade Glioma'] \n", "712 ['Glioblastoma'] \n", "\n", " TargetVec AgentJudgment \\\n", "82 [[-0.12244764715433121, -0.5778073668479919, -... None \n", "175 [[-0.33767956495285034, -0.4648125171661377, -... None \n", "263 [[-0.27501848340034485, -0.5264514088630676, -... None \n", "361 [[-0.21631155908107758, -0.5687925219535828, -... None \n", "414 [[-0.18604964017868042, -0.547483503818512, -0... None \n", "636 [[-0.2750183045864105, -0.5264511704444885, -0... None \n", "712 [[-0.15113382041454315, -0.5002245306968689, -... None \n", "\n", " AgentGrade \n", "82 None \n", "175 None \n", "263 None \n", "361 None \n", "414 None \n", "636 None \n", "712 None \n", "\n", "[7 rows x 43 columns]" ] }, "execution_count": 47, "metadata": {}, "output_type": "execute_result" } ], "source": [ "df" ] }, { "cell_type": "code", "execution_count": 48, "metadata": {}, "outputs": [ { "name": "stderr", "output_type": "stream", "text": [ "/var/folders/yw/qz00x75d7kb98f7vm8dkhkvw0000gn/T/ipykernel_49357/1375088122.py:1: SettingWithCopyWarning: \n", "A value is trying to be set on a copy of a slice from a DataFrame.\n", "Try using .loc[row_indexer,col_indexer] = value instead\n", "\n", "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n", " df['AgentJudgment'] = None\n", "/var/folders/yw/qz00x75d7kb98f7vm8dkhkvw0000gn/T/ipykernel_49357/1375088122.py:2: SettingWithCopyWarning: \n", "A value is trying to be set on a copy of a slice from a DataFrame.\n", "Try using .loc[row_indexer,col_indexer] = value instead\n", "\n", "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n", " df['AgentGrade'] = None\n" ] } ], "source": [ "\n", "df['AgentJudgment'] = None\n", "df['AgentGrade'] = None\n", "\n", "#Define agents\n", "#modifier = QuestionModifierEnglish(groq)\n", "CriteriaCheckAgent = SimpleClinicalTrialAgent(groq)\n", "grader_agent = GraderAgent(groq)" ] }, { "cell_type": "code", "execution_count": 49, "metadata": {}, "outputs": [ { "data": { "text/plain": [ "'Patients who meets any of the following criteria cannot participate in this clinical trial. -Diffuse Intrinsic Pontine Glioma (DIPG) or diffuse midline glioma located in the ? -Recurrent or refractory HGG including any recurrence/progression during/after radiotherapy. -Secondary HGG, defined as a previously treated low-grade glioma that now meets high- grade criteria, or that resulted from a previously treated malignancy. -Have known pathogenic somatic mutations appropriate for an anaplastic lymphoma kinase (ALK), B-rapidly accelerated fibrosarcoma (BRAF), or neurotrophic tyrosine receptor kinase (NTRK ) inhibitor, in regions where these therapies are available and deemed appropriate by the investigator. -Prior HGG treatment (including bevacizumab), except for surgery and radiotherapy (with or without concomitant temozolomide) -Current enrollment in another trial deemed. -Treatment with an investigational product within the last 30 days or 5 half-lives (whichever is longer). -Prior malignancy within the previous 3 years that, per the investigator and the medical monitor, may affect interpretation of study results. -A preexisting medical condition(s) that, per the investigator, would preclude study participation. -Any serious, active, systemic infection requiring IV antibiotic, antifungal, or antiviral therapy, including acute hepatitis B or C, or Human Immunodeficiency Virus at C1D1. -Intolerability or hypersensitivity such as urticaria, anaphylaxis, toxic necrolysis, and/or Stevens-Johnson syndrome, to temozolomide, its excipients, or dacarbazine. -Received a live virus vaccine within 28 days of C1D1. -Pregnant, breastfeeding, or intend to become pregnant during the study.'" ] }, "execution_count": 49, "metadata": {}, "output_type": "execute_result" } ], "source": [ "df.iloc[0,:]['Inclusion Criteria']\n", "df.iloc[0,:]['Exclusion Criteria']" ] }, { "cell_type": "code", "execution_count": 50, "metadata": {}, "outputs": [], "source": [ "def GetJRCTCriteria(dataframe, idx):\n", " InC = dataframe.iloc[idx,:]['Inclusion Criteria']\n", " ExC = dataframe.iloc[idx,:]['Exclusion Criteria']\n", " return \"Inclusion Criteria :\" + InC + \"\\n\" + \"Exclusion Criteria :\" + ExC" ] }, { "cell_type": "code", "execution_count": 51, "metadata": {}, "outputs": [], "source": [ "TargetCriteria = GetJRCTCriteria(df,0)" ] }, { "cell_type": "code", "execution_count": 52, "metadata": {}, "outputs": [ { "name": "stdout", "output_type": "stream", "text": [ "The patient is eligible for this clinical trial based on the provided information, as there are no exclusion criteria that would prevent him from participating.\n" ] } ], "source": [ "AgentJudgment = CriteriaCheckAgent.evaluate_eligibility(TargetCriteria, ex_question)\n", "print(AgentJudgment)" ] }, { "cell_type": "code", "execution_count": 53, "metadata": {}, "outputs": [], "source": [ "AgentGrade = grader_agent.evaluate_eligibility(AgentJudgment)" ] }, { "cell_type": "code", "execution_count": 54, "metadata": {}, "outputs": [ { "data": { "text/plain": [ "'yes'" ] }, "execution_count": 54, "metadata": {}, "output_type": "execute_result" } ], "source": [ "AgentGrade" ] }, { "cell_type": "code", "execution_count": 55, "metadata": {}, "outputs": [], "source": [ "ex_question = generate_ex_question_English(age, sex, TumorName, GeneMutation, Meseable, Biopsiable)" ] }, { "cell_type": "code", "execution_count": 56, "metadata": {}, "outputs": [ { "name": "stdout", "output_type": "stream", "text": [ "The patient is eligible for this clinical trial based on the provided information, as there are no exclusion criteria that would prevent him from participating.\n", "yes\n", "The patient is eligible for this clinical trial based on the provided information, as the patient meets the inclusion criteria (age, measurable and biopsiable tumor, and no exclusion criteria mentioned).\n", "yes\n", "The patient is not eligible for this clinical trial because the patient's age (65) exceeds the upper limit of 75 years old specified in inclusion criterion (7).\n", "no\n", "Based on the provided information, the patient is eligible for this clinical trial. The patient meets the inclusion criteria for Cohort 1, as they have a glioma (WHO Grade 2-4) diagnosed by pathological diagnosis of resection or biopsy, have a history of chemotherapy or radiation therapy, and have measurable lesions based on the RANO criteria. The patient's age of 65 meets the age requirement, and there is no mention of any exclusion criteria that would prevent the patient from participating.\n", "yes\n", "The patient is not eligible for this clinical trial because the inclusion criteria specify that patients must have a BRAF fusion or rearrangement, but the patient has a HER2 gene mutation.\n", "no\n", "Based on the provided criteria, the 65-year-old male patient with glioma appears to be eligible for this clinical trial, as there are no specific age restrictions or exclusions mentioned. However, I do not know if the patient meets the other inclusion criteria, such as Karnofsky Performance Status (KPS) score, adequate organ function, and recovery from prior therapy, as this information is not provided.\n", "unclear\n", "The patient is eligible for this clinical trial based on the provided information, as the patient meets the inclusion criteria (age, measurable tumor, biopsiable tumor) and does not have any obvious exclusions (e.g., no mention of corticosteroids, immunosuppressive agents, or other exclusion criteria). However, some information is missing, such as Karnofsky Performance Status, neutrophil count, hemoglobin, platelet count, and other lab values, which would need to be confirmed to ensure full eligibility.\n", "unclear\n" ] } ], "source": [ "for i in range(len(df)):\n", " TargetCriteria = GetJRCTCriteria(df, i)\n", " AgentJudgment = CriteriaCheckAgent.evaluate_eligibility(TargetCriteria, ex_question)\n", " print(AgentJudgment)\n", " AgentGrade = grader_agent.evaluate_eligibility(AgentJudgment)\n", " print(AgentGrade)\n", " \n", " # df.locを使って値を代入（行・列名で指定）\n", " df.loc[df.index[i], 'AgentJudgment'] = AgentJudgment\n", " df.loc[df.index[i], 'AgentGrade'] = AgentGrade\n" ] }, { "cell_type": "markdown", "metadata": {}, "source": [ "for i in range(len(df)):\n", " TargetCriteria = GetJRCTCriteria(df,i)\n", " AgentJudgment = CriteriaCheckAgent.evaluate_eligibility(TargetCriteria, ex_question)\n", " print(AgentJudgment)\n", " AgentGrade = grader_agent.evaluate_eligibility(AgentJudgment)\n", " print(AgentGrade)\n", " df.iloc[i,:]['AgentJudgment'] = AgentJudgment\n", " df.iloc[i,:]['AgentJudgment'] = AgentGrade\n" ] }, { "cell_type": "markdown", "metadata": {}, "source": [] }, { "cell_type": "code", "execution_count": 58, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDNCT NoJapicCTI NoTitleTargetJTargetTargetEnglish研究・治験の目的試験等のフェーズ試験の種類...Age MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)TargetWordTargetVecAgentJudgmentAgentGrade
82jRCT2051240121NCT06413706NaN放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...悪性神経膠腫悪性神経膠腫High-Grade Glioma放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...2NaN...No limit21age old notNaNNaNNaNDrug: Abemaciclib Administered orally Other Na...['High-Grade Glioma'][[-0.12244764715433121, -0.5778073668479919, -...The patient is eligible for this clinical tria...yes
175jRCT2031240090NaNNaN再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...悪性神経膠腫悪性神経膠腫Malignant glioma再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl...3NaN...18age old over75age old underBothNaNglioblastoma, grade3/4 astrocytoma, grade3 oli...Group A: BPC Therapy Depending on the patient'...['Malignant Glioma'][[-0.33767956495285034, -0.4648125171661377, -...The patient is eligible for this clinical tria...yes
263jRCT2041230136NaNNaN再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験再発膠芽腫再発膠芽腫recurrent glioblastoma再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を...1NaN...18age old over75age old underBothNaNNaNDosing frequency: 1 time /week Dose Levels Lev...['Recurrent', 'Glioblastoma'][[-0.27501848340034485, -0.5264514088630676, -...The patient is not eligible for this clinical ...no
361jRCT2051230069NaNNaN神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...神経膠腫神経膠腫Glioma神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併用療法の安全...1NaN...18age old overNo limitBothNaNNaN<cohort1> Lomustine 130 mg/m2 orally every 6 w...['Glioma'][[-0.21631155908107758, -0.5687925219535828, -...Based on the provided information, the patient...yes
414jRCT2031230007NaNNaNBRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医...低悪性度神経膠腫、膵癌低悪性度神経膠腫、膵癌Low-grade glioma, pancreatic cancerBRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫(コホート A...2NaN...12age old overNo limitBothNaNBRAF fusion gene, BRAF rearrangement, low-grad...Binimetinib is administered 45 mg orally, twic...['Low-Grade Glioma', 'Pancreatic Cancer'][[-0.18604964017868042, -0.547483503818512, -0...The patient is not eligible for this clinical ...no
636jRCT2031210299NaNNaN再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験再発悪性神経膠腫再発悪性神経膠腫Recurrent High-Grade Glioma再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...1NaN...18age old overNo limitBothNaNNaNPatients will receive DSP-0390 orally once dai...['Recurrent', 'High-Grade Glioma'][[-0.2750183045864105, -0.5264511704444885, -0...Based on the provided criteria, the 65-year-ol...unclear
712jRCT2031200153NaNNaNCellm-001による初発膠芽腫治療効果無作為比較対照試験膠芽腫膠芽腫glioblastoma脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...3NaN...18age old over75age old underBothNaNNaNInject the investigational drug (Cellm-001 or ...['Glioblastoma'][[-0.15113382041454315, -0.5002245306968689, -...The patient is eligible for this clinical tria...unclear
\n", "

7 rows × 43 columns

\n", "
" ], "text/plain": [ " JRCT ID NCT No JapicCTI No \\\n", "82 jRCT2051240121 NCT06413706 NaN \n", "175 jRCT2031240090 NaN NaN \n", "263 jRCT2041230136 NaN NaN \n", "361 jRCT2051230069 NaN NaN \n", "414 jRCT2031230007 NaN NaN \n", "636 jRCT2031210299 NaN NaN \n", "712 jRCT2031200153 NaN NaN \n", "\n", " Title TargetJ \\\n", "82 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... 悪性神経膠腫 \n", "175 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... 悪性神経膠腫 \n", "263 再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験 再発膠芽腫 \n", "361 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 神経膠腫 \n", "414 BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医... 低悪性度神経膠腫、膵癌 \n", "636 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 再発悪性神経膠腫 \n", "712 Cellm-001による初発膠芽腫治療効果無作為比較対照試験 膠芽腫 \n", "\n", " Target TargetEnglish \\\n", "82 悪性神経膠腫 High-Grade Glioma \n", "175 悪性神経膠腫 Malignant glioma \n", "263 再発膠芽腫 recurrent glioblastoma \n", "361 神経膠腫 Glioma \n", "414 低悪性度神経膠腫、膵癌 Low-grade glioma, pancreatic cancer \n", "636 再発悪性神経膠腫 Recurrent High-Grade Glioma \n", "712 膠芽腫 glioblastoma \n", "\n", " 研究・治験の目的 試験等のフェーズ 試験の種類 ... \\\n", "82 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... 2 NaN ... \n", "175 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl... 3 NaN ... \n", "263 再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を... 1 NaN ... \n", "361 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併用療法の安全... 1 NaN ... \n", "414 BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫(コホート A... 2 NaN ... \n", "636 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... 1 NaN ... \n", "712 脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術... 3 NaN ... \n", "\n", " Age Minimum Age Maximum Gender Discontinuation Criteria \\\n", "82 No limit 21age old not NaN NaN \n", "175 18age old over 75age old under Both NaN \n", "263 18age old over 75age old under Both NaN \n", "361 18age old over No limit Both NaN \n", "414 12age old over No limit Both NaN \n", "636 18age old over No limit Both NaN \n", "712 18age old over 75age old under Both NaN \n", "\n", " Keyword \\\n", "82 NaN \n", "175 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n", "263 NaN \n", "361 NaN \n", "414 BRAF fusion gene, BRAF rearrangement, low-grad... \n", "636 NaN \n", "712 NaN \n", "\n", " Intervention(s) \\\n", "82 Drug: Abemaciclib Administered orally Other Na... \n", "175 Group A: BPC Therapy Depending on the patient'... \n", "263 Dosing frequency: 1 time /week Dose Levels Lev... \n", "361 Lomustine 130 mg/m2 orally every 6 w... \n", "414 Binimetinib is administered 45 mg orally, twic... \n", "636 Patients will receive DSP-0390 orally once dai... \n", "712 Inject the investigational drug (Cellm-001 or ... \n", "\n", " TargetWord \\\n", "82 ['High-Grade Glioma'] \n", "175 ['Malignant Glioma'] \n", "263 ['Recurrent', 'Glioblastoma'] \n", "361 ['Glioma'] \n", "414 ['Low-Grade Glioma', 'Pancreatic Cancer'] \n", "636 ['Recurrent', 'High-Grade Glioma'] \n", "712 ['Glioblastoma'] \n", "\n", " TargetVec \\\n", "82 [[-0.12244764715433121, -0.5778073668479919, -... \n", "175 [[-0.33767956495285034, -0.4648125171661377, -... \n", "263 [[-0.27501848340034485, -0.5264514088630676, -... \n", "361 [[-0.21631155908107758, -0.5687925219535828, -... \n", "414 [[-0.18604964017868042, -0.547483503818512, -0... \n", "636 [[-0.2750183045864105, -0.5264511704444885, -0... \n", "712 [[-0.15113382041454315, -0.5002245306968689, -... \n", "\n", " AgentJudgment AgentGrade \n", "82 The patient is eligible for this clinical tria... yes \n", "175 The patient is eligible for this clinical tria... yes \n", "263 The patient is not eligible for this clinical ... no \n", "361 Based on the provided information, the patient... yes \n", "414 The patient is not eligible for this clinical ... no \n", "636 Based on the provided criteria, the 65-year-ol... unclear \n", "712 The patient is eligible for this clinical tria... unclear \n", "\n", "[7 rows x 43 columns]" ] }, "execution_count": 58, "metadata": {}, "output_type": "execute_result" } ], "source": [ "df" ] }, { "cell_type": "code", "execution_count": 59, "metadata": {}, "outputs": [ { "data": { "text/plain": [ "Index(['JRCT ID', 'NCT No', 'JapicCTI No', 'Title', 'TargetJ', 'Target',\n", " 'TargetEnglish', '研究・治験の目的', '試験等のフェーズ', '試験の種類', '無作為化', '盲検化', '対照',\n", " '割付け', '研究目的', '主たる選択基準', '主たる除外基準', '年齢下限', '年齢上限', '性別', '中止基準',\n", " '対象疾患キーワード', '介入の内容', 'URL', 'Phase', 'Study Type', 'allocation',\n", " 'masking', 'control', 'assignment', 'purpose', 'Inclusion Criteria',\n", " 'Exclusion Criteria', 'Age Minimum', 'Age Maximum', 'Gender',\n", " 'Discontinuation Criteria', 'Keyword', 'Intervention(s)', 'TargetWord',\n", " 'TargetVec', 'AgentJudgment', 'AgentGrade'],\n", " dtype='object')" ] }, "execution_count": 59, "metadata": {}, "output_type": "execute_result" } ], "source": [ "df.columns" ] }, { "cell_type": "code", "execution_count": 62, "metadata": {}, "outputs": [], "source": [ " # 列を指定した順に並び替え\n", "columns_order = ['JRCT ID', 'Title', '研究・治験の目的','AgentJudgment', 'AgentGrade','主たる選択基準', '主たる除外基準','Inclusion Criteria','Exclusion Criteria','NCT No', 'JapicCTI No']\n", "df = df[columns_order]" ] }, { "cell_type": "code", "execution_count": 63, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDTitle研究・治験の目的AgentJudgmentAgentGrade主たる選択基準主たる除外基準Inclusion CriteriaExclusion CriteriaNCT NoJapicCTI No
82jRCT2051240121放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...The patient is eligible for this clinical tria...yes以下の基準をすべて満たす必要がある ‐生検によって、以下に示す2016 年WHO分類グレード...以下の基準のいずれかに該当する場合、本治験へ参加できない。 ‐びまん性橋膠腫(diffuse...Subjects required to meet all the folloiwng cr...Patients who meets any of the following criter...NCT06413706NaN
175jRCT2031240090再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl...The patient is eligible for this clinical tria...yes1) 登録前直近の病理診断により組織学的にWHO2021に基づく悪性神経膠腫(膠芽腫または、...1) 登録前2年以内の他の悪性腫瘍の既往または合併を有する。ただし局所治療により治癒と判断さ...1) Histologically diagnosed as high grade glio...1) Have a history or merger of other malignanc...NaNNaN
263jRCT2041230136再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を...The patient is not eligible for this clinical ...no(1)手術摘出検体又は生検検体の永久標本にて、組織学的に膠芽腫と診断されている患者 (2)標...(1)脳外転移のある患者 (2)著明な頭蓋内圧亢進症状のある患者 (3)初発時又は再発・増悪...(1) Patients with a histological diagnosis of ...(1) Patients with extracerebral metastases. (2...NaNNaN
361jRCT2051230069神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併用療法の安全...Based on the provided information, the patient...yes<コホート1>以下のすべての項目を満たすものとする。 1)摘出術又は生検の病理診断にて、神経...<コホート1、コホート2共通> 1) 活動性の重複がんを有する(同時性重複がん/多発がん及び...<Cohort 1> All of the following items shall be...<Common to Cohort 1 and Cohort 2> 1) Active mu...NaNNaN
414jRCT2031230007BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医...BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫(コホート A...The patient is not eligible for this clinical ...noコホートA、コホートB共通の適格規準 1) 保険診療下で行われているNGSを用いたがん遺伝子...1) 活動性の重複がんを有する(ただし、次の1~3は除外しない:1完全切除された以下のがん:...Inclusion criteria for both cohort A and B 1) ...1) Active double primary cancer (but not (1)-(...NaNNaN
636jRCT2031210299再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...Based on the provided criteria, the 65-year-ol...unclear1. 3ヵ月以上の生存が見込める患者 2. 前治療(化学療法、手術又は放射線療法)による副作...1. Day 1前の3ヵ月以内にベバシズマブ又はその他の血管内皮増殖因子(VEGF)阻害薬に...1. Estimated life expectancy >= 3 months 2. Re...1. Prior therapy with bevacizumab or other ant...NaNNaN
712jRCT2031200153Cellm-001による初発膠芽腫治療効果無作為比較対照試験脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...The patient is eligible for this clinical tria...unclear(1)年齢は満18歳以上、75歳以下である。 (2)テント上の膠芽腫(WHO Grade I...(1)登録前14日以内の副腎皮質ステロイド剤(10mg/日超のプレドニゾロン、あるいは相当量...(1) 18 years old or older and 75 years old or ...(1) Systemic administration of corticosteroids...NaNNaN
\n", "
" ], "text/plain": [ " JRCT ID Title \\\n", "82 jRCT2051240121 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... \n", "175 jRCT2031240090 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... \n", "263 jRCT2041230136 再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験 \n", "361 jRCT2051230069 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... \n", "414 jRCT2031230007 BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医... \n", "636 jRCT2031210299 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 \n", "712 jRCT2031200153 Cellm-001による初発膠芽腫治療効果無作為比較対照試験 \n", "\n", " 研究・治験の目的 \\\n", "82 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... \n", "175 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl... \n", "263 再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を... \n", "361 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併用療法の安全... \n", "414 BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫(コホート A... \n", "636 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... \n", "712 脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術... \n", "\n", " AgentJudgment AgentGrade \\\n", "82 The patient is eligible for this clinical tria... yes \n", "175 The patient is eligible for this clinical tria... yes \n", "263 The patient is not eligible for this clinical ... no \n", "361 Based on the provided information, the patient... yes \n", "414 The patient is not eligible for this clinical ... no \n", "636 Based on the provided criteria, the 65-year-ol... unclear \n", "712 The patient is eligible for this clinical tria... unclear \n", "\n", " 主たる選択基準 \\\n", "82 以下の基準をすべて満たす必要がある ‐生検によって、以下に示す2016 年WHO分類グレード... \n", "175 1) 登録前直近の病理診断により組織学的にWHO2021に基づく悪性神経膠腫(膠芽腫または、... \n", "263 (1)手術摘出検体又は生検検体の永久標本にて、組織学的に膠芽腫と診断されている患者 (2)標... \n", "361 <コホート1>以下のすべての項目を満たすものとする。 1)摘出術又は生検の病理診断にて、神経... \n", "414 コホートA、コホートB共通の適格規準 1) 保険診療下で行われているNGSを用いたがん遺伝子... \n", "636 1. 3ヵ月以上の生存が見込める患者 2. 前治療(化学療法、手術又は放射線療法)による副作... \n", "712 (1)年齢は満18歳以上、75歳以下である。 (2)テント上の膠芽腫(WHO Grade I... \n", "\n", " 主たる除外基準 \\\n", "82 以下の基準のいずれかに該当する場合、本治験へ参加できない。 ‐びまん性橋膠腫(diffuse... \n", "175 1) 登録前2年以内の他の悪性腫瘍の既往または合併を有する。ただし局所治療により治癒と判断さ... \n", "263 (1)脳外転移のある患者 (2)著明な頭蓋内圧亢進症状のある患者 (3)初発時又は再発・増悪... \n", "361 <コホート1、コホート2共通> 1) 活動性の重複がんを有する(同時性重複がん/多発がん及び... \n", "414 1) 活動性の重複がんを有する(ただし、次の1~3は除外しない:1完全切除された以下のがん:... \n", "636 1. Day 1前の3ヵ月以内にベバシズマブ又はその他の血管内皮増殖因子(VEGF)阻害薬に... \n", "712 (1)登録前14日以内の副腎皮質ステロイド剤(10mg/日超のプレドニゾロン、あるいは相当量... \n", "\n", " Inclusion Criteria \\\n", "82 Subjects required to meet all the folloiwng cr... \n", "175 1) Histologically diagnosed as high grade glio... \n", "263 (1) Patients with a histological diagnosis of ... \n", "361 All of the following items shall be... \n", "414 Inclusion criteria for both cohort A and B 1) ... \n", "636 1. Estimated life expectancy >= 3 months 2. Re... \n", "712 (1) 18 years old or older and 75 years old or ... \n", "\n", " Exclusion Criteria NCT No \\\n", "82 Patients who meets any of the following criter... NCT06413706 \n", "175 1) Have a history or merger of other malignanc... NaN \n", "263 (1) Patients with extracerebral metastases. (2... NaN \n", "361 1) Active mu... NaN \n", "414 1) Active double primary cancer (but not (1)-(... NaN \n", "636 1. Prior therapy with bevacizumab or other ant... NaN \n", "712 (1) Systemic administration of corticosteroids... NaN \n", "\n", " JapicCTI No \n", "82 NaN \n", "175 NaN \n", "263 NaN \n", "361 NaN \n", "414 NaN \n", "636 NaN \n", "712 NaN " ] }, "execution_count": 63, "metadata": {}, "output_type": "execute_result" } ], "source": [ "df" ] }, { "cell_type": "code", "execution_count": 5, "metadata": {}, "outputs": [], "source": [ " # 列を指定した順に並び替え\n", "columns_order = ['NCTID', 'AgentGrade', 'Title', 'AgentJudgment', 'Japanes Locations', \n", " 'Primary Completion Date', 'Cancer', 'Summary', 'Eligibility Criteria']\n", "df = df[columns_order] " ] }, { "cell_type": "code", "execution_count": 6, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
NCTIDAgentGradeTitleAgentJudgmentJapanes LocationsPrimary Completion DateCancerSummaryEligibility Criteria
0NCT05580562noONC201 in H3 K27M-mutant Diffuse Glioma Follow...The patient is not eligible for this clinical ...Chuo City, Fukuoka, Kyoto, Osaka, Sapporo2026-08H3 K27M, GliomaThis is a randomized, double-blind, placebo-co...Inclusion Criteria:\\n\\n1. Able to understand t...
1NCT06413706yesA Study Comparing Abemaciclib Plus Temozolomid...The patient is eligible for this clinical tria...Nagoya, Osaka, Tokyo2027-07GliomaThe purpose of this study is to measure the be...Inclusion Criteria:\\n\\n* Biopsy proven high-gr...
2NCT05503264noA Study To Evaluate The Efficacy, Safety, Phar...The patient is not eligible for this clinical ...Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyogo, ...2026-06-23NMDAR Autoimmune Encephalitis, LGI1 Autoimmune...The purpose of this study is to assess the eff...Inclusion Criteria:\\n\\n* Reasonable exclusion ...
3NCT06159478noBinimetinib in Patients With BRAF Fusion-posit...The patient is not eligible for this clinical ...Fukuoka, Kashiwa, Kyoto City, Sapporo, Sendai, ku2027-02-28Low-grade Glioma, Pancreatic CancerThis study is an open-label, parallel, 2-cohor...Inclusion Criteria:\\n\\nInclusion criteria for ...
\n", "
" ], "text/plain": [ " NCTID AgentGrade Title \\\n", "0 NCT05580562 no ONC201 in H3 K27M-mutant Diffuse Glioma Follow... \n", "1 NCT06413706 yes A Study Comparing Abemaciclib Plus Temozolomid... \n", "2 NCT05503264 no A Study To Evaluate The Efficacy, Safety, Phar... \n", "3 NCT06159478 no Binimetinib in Patients With BRAF Fusion-posit... \n", "\n", " AgentJudgment \\\n", "0 The patient is not eligible for this clinical ... \n", "1 The patient is eligible for this clinical tria... \n", "2 The patient is not eligible for this clinical ... \n", "3 The patient is not eligible for this clinical ... \n", "\n", " Japanes Locations Primary Completion Date \\\n", "0 Chuo City, Fukuoka, Kyoto, Osaka, Sapporo 2026-08 \n", "1 Nagoya, Osaka, Tokyo 2027-07 \n", "2 Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyogo, ... 2026-06-23 \n", "3 Fukuoka, Kashiwa, Kyoto City, Sapporo, Sendai, ku 2027-02-28 \n", "\n", " Cancer \\\n", "0 H3 K27M, Glioma \n", "1 Glioma \n", "2 NMDAR Autoimmune Encephalitis, LGI1 Autoimmune... \n", "3 Low-grade Glioma, Pancreatic Cancer \n", "\n", " Summary \\\n", "0 This is a randomized, double-blind, placebo-co... \n", "1 The purpose of this study is to measure the be... \n", "2 The purpose of this study is to assess the eff... \n", "3 This study is an open-label, parallel, 2-cohor... \n", "\n", " Eligibility Criteria \n", "0 Inclusion Criteria:\\n\\n1. Able to understand t... \n", "1 Inclusion Criteria:\\n\\n* Biopsy proven high-gr... \n", "2 Inclusion Criteria:\\n\\n* Reasonable exclusion ... \n", "3 Inclusion Criteria:\\n\\nInclusion criteria for ... " ] }, "execution_count": 6, "metadata": {}, "output_type": "execute_result" } ], "source": [ "df" ] }, { "cell_type": "code", "execution_count": null, "metadata": {}, "outputs": [], "source": [] } ], "metadata": { "kernelspec": { "display_name": "gradio", "language": "python", "name": "python3" }, "language_info": { "codemirror_mode": { "name": "ipython", "version": 3 }, "file_extension": ".py", "mimetype": "text/x-python", "name": "python", "nbconvert_exporter": "python", "pygments_lexer": "ipython3", "version": "3.12.3" } }, "nbformat": 4, "nbformat_minor": 2 }